Praetego’s progress is routinely updated as we strive to enter clinical trials.
Please check back frequently for news, announcements, and events.
January 2, 2020
After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant to continue preclinical development of novel Amadorins against Diabetic Peripheral Neuropathy. This award would provide preclinical proof of concept in multiple animal models of Type 1 and Type 2 diabetic neuropathy.
